Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Have Cytokinetics insiders bought shares recently?
No open-market purchase by an insider of Cytokinetics was filed in the last 90 days. The latest on record was on Dec 11, 2019.
How often do Cytokinetics insiders buy and sell shares?
Since 2006, Cytokinetics insiders reported 33 open-market purchases and 1,370 sales on Forms 4 and 5, with purchases in 6 different years, most recently 2019.
Who is selling Cytokinetics stock?
In the last 90 days, 6 insiders of Cytokinetics (CYTK) reported 23 open-market sales worth $13.3M in total on SEC Form 4. The largest seller by value was Robert I Blum, with $9.7M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade CYTK?
Yes. Members of Congress disclosed 2 trades in Cytokinetics (CYTK) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent is from Rep. Gilbert Ray Cisneros Jr. (CA31).
When does Cytokinetics report its next results?
Cytokinetics's next results are expected on Feb 22, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−20.6% (−$13.33) from Nov 19, 2025 to Nov 19, 2026 · adjusted daily closes
Adjusted close went from $64.79 on Nov 19, 2025 to $51.46 on Nov 19, 2026 (−20.6%). Disclosed in this range: 0 insider trades, 91 pre-arranged insider sales, 2 Congress trades, and 22 13F position changes for 3 quarters ending in it.
$40$60$70$80$90$100$51.46
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 93 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biotechnology company based in South San Francisco, California.
Last 12 months
−20.6%
S&P 500 +8.0% over the same dates
Market value
$7.17B
Close of Nov 19, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 17.9M shares sold short (12.9% of shares outstanding), −3.8% vs the previous count, 14.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insider buying and selling since 2006
Insiders of Cytokinetics reported 33 open-market purchases and 1,370 sales since 2006; purchases in 6 different years, most recently 2019.
Year
Bought
Sold
2026
—
$45.1M81×81 trades
2025
—
$23.8M75×75 trades
2024
—
$30.8M75×75 trades
2023
—
$13.5M46×46 trades
2022
—
$23.9M46×46 trades
2021
—
$19.1M86×86 trades
2020
—
$34.7M74×74 trades
2019
$3.28M7×7 trades
$657K20×20 trades
2018
—
$401K23×23 trades
2017
—
$3.2M165×165 trades
2016
—
$70K4×4 trades
2015
$130K15×15 trades
$171K4×4 trades
2014
$4.04M3×3 trades
$146K5×5 trades
2012
—
$1.06M1×1 trade
2010
—
$3.41M53×53 trades
2009
$3M1×1 trade
$1.67M204×204 trades
2008
—
$464K81×81 trades
2007
$101K1×1 trade
$1.16M127×127 trades
2006
$290K6×6 trades
$1.81M200×200 trades
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Since Nov 18, 2025, CYTK is down 22.2% and the index fund is up 8.5%: 31 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much CYTK moves
A usual day
±1.5%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
5.1%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−12.7%Nov 5, 2026
Largest one-day rise
+16.7%May 5, 2026
Deepest fall of the year
−41.2%From the close of Jun 29, 2026 to Nov 18, 2026.
Days of 5% or more
14Out of 252 sessions, in either direction.
Beta 1.0(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 250 trading days (1 = in step with it).
Late-stage clinical trials
4 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in symptomatic non-obstructive hypertrophic cardiomyopathy, symptomatic heart failure with preserved ejection fraction (hfpef), heart failure. The ones with the nearest registered primary completion date still ahead:
2 trials have a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Last 30 days
Written by software from the filings listed below · Oct 26, 2026
Insiders. In the 30 days to Oct 26, 2026, insiders filed 0 open-market purchases and 4 open-market sales (about $1.4M, by 2 people). Cytokinetics on OQRO
4 more points, with the facts they come from, are in OQRO Pro.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Cytokinetics filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 90 open-market sales (about $52.9M, in 78 filings, by 11 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 74 open-market sales (about $17.2M, in 72 filings). (Cytokinetics on OQRO)
Congress. Members of Congress filed 2 disclosures on Cytokinetics in the 12 months to Nov 19, 2026: 2 purchases and 0 sales, by 1 member. In the 12 months before that: 3 disclosures. The largest range: Rep. Gilbert Ray Cisneros Jr. (CA31), $1,001 to $15,000, filed Oct 12, 2026.
Funds and stakes. Fund 13F filings recorded in the 12 months show 15 new or larger positions and 7 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. FDA records list 1 drug approval for Cytokinetics between Nov 19, 2025 and Nov 19, 2026; the latest, on Nov 13, 2026: drug approval for Myqorzo (New use approved (efficacy supplement). Active ingredient: Aficamten). ClinicalTrials.gov shows 5 studys sponsored by the company updated in the period; the latest, "Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Frac..." (Phase 3, status recruiting), was updated on Nov 4, 2026, with primary completion listed for 2027-09.
Company reports, price and press. Cytokinetics filed a Form 8-K on Nov 4, 2026 (Item 2.02) that OQRO classes as: reported its results. Cytokinetics filed a Form 8-K on Aug 6, 2026 (Item 2.02) that OQRO classes as: reported its results.
Who holds it. 478 funds reported a stake in Cytokinetics in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (12.5% of the value reported), T. Rowe Price Investment Management, Inc. (11.7% of the value reported), WELLINGTON MANAGEMENT GROUP LLP (4.3% of the value reported).
Attention. The English Wikipedia article on Cytokinetics was read about 12 times a day in the 7 days to Nov 18, 2026, against a usual 14 a day over the 90 days before. Reads measure attention, not buying or selling.
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Cytokinetics filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 90 open-market sales (about $52.9M, in 78 filings, by 11 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 74 open-market sales (about $17.2M, in 72 filings).
The largest sale: Robert I Blum, President & CEO, about $6.79M, filed Sep 15, 2026.
Congress
Members of Congress filed 2 disclosures on Cytokinetics in the 12 months to Nov 19, 2026: 2 purchases and 0 sales, by 1 member. In the 12 months before that: 3 disclosures.
The largest range: Rep. Gilbert Ray Cisneros Jr. (CA31), $1,001 to $15,000, filed Oct 12, 2026.
Funds and stakes
Fund 13F filings recorded in the 12 months show 15 new or larger positions and 7 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
FDA records list 1 drug approval for Cytokinetics between Nov 19, 2025 and Nov 19, 2026; the latest, on Nov 13, 2026: drug approval for Myqorzo (New use approved (efficacy supplement). Active ingredient: Aficamten).
ClinicalTrials.gov shows 5 studys sponsored by the company updated in the period; the latest, "Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Frac..." (Phase 3, status recruiting), was updated on Nov 4, 2026, with primary completion listed for 2027-09.
FINRA short interest for CYTK on the settlement date of Oct 30, 2026 was 17,929,635 shares (-3.75% on the previous report), about 14.15 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Avoro Capital Advisors LLC (increased, 1,666,666 shares); RTW Investments, LP (increased, 140,845 shares); the largest that shrank: Paradigm Biocapital Advisors LP (sold out); Capital International Investors (reduced, 32,955 shares). A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $11.9M for its principal executive officer, and an average of $4.53M for the other named executive officers.
Company reports, price and press
Cytokinetics filed a Form 8-K on Nov 4, 2026 (Item 2.02) that OQRO classes as: reported its results.
Cytokinetics filed a Form 8-K on Aug 6, 2026 (Item 2.02) that OQRO classes as: reported its results.
Cytokinetics filed a Form 8-K on May 5, 2026 (Item 2.02) that OQRO classes as: reported its results.
Press coverage listed by Finnhub: "Cytokinetics Touts MYQORZO Launch Momentum, Plans New FDA Filing" (Yahoo, Nov 17, 2026).
Press coverage listed by Finnhub: "Cytokinetics’ MYQORZO Gains Ground as Company Plans Push Into New Heart-Disease Market" (Yahoo, Nov 16, 2026).
Press coverage listed by Finnhub: "FDA Decision Watch: Summit’s Lung Cancer Drug, Cytokinetics’ Heart Therapy And Teva’s Igalmi In Spotlight This Week" (Yahoo, Nov 9, 2026).
CYTK closed at $51.32 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $62.65 to $51.32, a change of −18.1%.
Who holds it
478 funds reported a stake in Cytokinetics in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (12.5% of the value reported), T. Rowe Price Investment Management, Inc. (11.7% of the value reported), WELLINGTON MANAGEMENT GROUP LLP (4.3% of the value reported).
Attention
The English Wikipedia article on Cytokinetics was read about 12 times a day in the 7 days to Nov 18, 2026, against a usual 14 a day over the 90 days before. Reads measure attention, not buying or selling.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
People read Cytokinetics's Wikipedia article about 11 times a day over the last week, close to the 14 on a usual day of the three months before.
May 15, 2026Busiest day: 38 views on Jul 21, 2026Nov 20, 2026
Views of the article Cytokinetics, by people (Wikimedia leaves out known bots). More readers means more attention, from news, results or anything else; it does not say anyone bought or sold. Source: Wikimedia pageviews.
5 certified in FY2026 Q3, vs 5 a year earlier. 5 positions in total, median offered wage $140K a year.
Medical Director, Clinical Research Cardiovascular · 1Scientist I · 1Senior Manager, Quality Validation · 1Senior Research Associate · 1Sr. Regulatory Affairs Associate I · 1
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
FDA, last 12 months
1 approval or clearance and 0 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Where the revenue comes from
Latest quarter
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Nov 4, 2026. Quarterly reports are not audited. Read the filing
By product or service
Net Product Revenue$44.5M94%
$0 the same quarter a year earlier
Collaboration Revenues$3.05M6.4%
+58% on the same quarter a year earlier ($1.94M)
License and Milestone Revenues$00.0%
$0 the same quarter a year earlier
Total revenue$47.6M+2356%
The full fiscal year ended Dec 31, 2025
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 26, 2026. Read the filing
By product or service
License and Milestone Revenues$79.4M90%
+429% on the year before ($15M)
Collaboration Revenues$8.69M9.9%
+150% on the year before ($3.47M)
Total revenue$88M+377%
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 9,000 words.
From “Overview”, in the company's words
We are a biopharmaceutical company focused on discovering, developing and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. We have discovered and are developing muscle-directed investigational medicines that may potentially improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. Our research and development activities relating to the biology of muscle function have evolved from our knowledge and expertise regarding the cytoskeleton, a complex biological infrastructure that plays a fundamental role within every human cell.
What the section covers (31 headings)
Overview
Liquidity and Capital Resources
Sources and Uses of Cash
Cash Flows Used in Operating Activities
Cash Flows Used in Investing Activities
Cash Flows Provided by Financing Activities
2024 Royalty Pharma Transactions
2022 Royalty Pharma Transactions
RP Aficamten Royalty Purchase Agreement
2017 RP Omecamtiv Mecarbil Royalty Purchase Agreement
Convertible Notes
Greater China Out-license for Omecamtiv Mecarbil
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026 and Form 10-Q filed Nov 4, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Greater China Out-license for Aficamten
Japan Out-license for Aficamten
And 17 more headings in the filing.
Risk factors in the annual report
Latest annual report filed Feb 26, 2026, compared with the one filed Feb 27, 2025. Read the filing
New risk factors in the latest annual report (4 headings)
If the FDA or comparable foreign regulatory authorities approve generic versions of MYQORZO, or any other potential products that receive marketing approval, or such authorities do not grant MYQORZO appropriate periods of data or market exclusivity before approving a generic version, sales of MYQORZO could be adversely affected.
Disruptions at the FDA, including due to a reduction in the FDA’s workforce and/or inadequate funding for the FDA, could prevent the FDA from performing normal functions on which our business relies, which could negatively impact our business.
Infringement lawsuits are costly and time-consuming, and an unfavorable outcome could have a significant adverse effect on our business, including our ability to market MYQORZO to the fullest extent permissible within regulatory approvals.
Litigation may substantially increase our costs and harm our business.
No longer listed (5 headings from the year before)
If we are sued for infringing third-party intellectual property rights, it will be costly and time-consuming, and an unfavorable outcome could have a significant adverse effect on our business.
We may undertake infringement or other legal proceedings against third parties, causing us to spend substantial resources on litigation and exposing our own intellectual property portfolio to challenge.
We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that we or our employees have wrongfully used or disclosed trade secrets of their former employers.
We may not be entitled to obtain additional loan disbursements under the RP Multi Tranche Loan Agreement.
We are obligated to maintain proper and effective internal control over financial reporting. In the future, we may not complete our execution of our internal control over financial reporting in a timely manner, or these internal controls may not be determined to be effective, which may result in material misstatements in our consolidated financial statements and may adversely affect investor confidence in our company and, as a result, the value of our common stock.
Legal proceedings (Item 3)
Judah Seidman, Individually and on Behalf of All Others Similarly Situated, Plaintiff, v. Cytokinetics, Incorporated and Robert I. Blum, Civil Action No.: 3:25-cv-07923 On September 17, 2025, a stockholder class action lawsuit (the "Action") was filed against the Company and its chief executive officer in the United States District Court for the Northern District of California, alleging certain violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Latest results: quarter ending Sep 30, 2026
Revenue
$47.6M
+2356.5% vs the same quarter a year earlier
Free cash flow, last 12 months
−$589M
This quarter −$125M, a year earlier −$117M
Net debt
$215M
Debt $419M, cash $203M, at Sep 30, 2026
Net income, last 12 months
−$778M
Operating loss: profit did not cover interest (latest fiscal year)
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 4, 2026.
Off-exchange trading: 43.5% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (29.3% on ATS, 14.2% with other brokers), close to its 26-week average of 45.2%. Weeks of Sep 21 to Oct 16, 2026.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: UBS ATS (12.7%), INTELLIGENT CROSS LLC (11.3%), INSTINCT X (9.1%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
When insiders usually buy
Last results
Nov 4, 2026
Within the 30 days after it, until Dec 4, 2026
Next results, expected
Feb 22, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Cytokinetics's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Cytokinetics's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.